Seeking Alpha analyst Stephen Ayers shares his views on which weight-loss drug stock looks most attractive for investors ...

Obesity drug developers Structure Therapeutics (NASDAQ:GPCR) and Metsera (NASDAQ:MTSR) recorded sharp gains alongside Eli ...

Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...

Eli Lilly (NYSE:LLY) shares climbed ~14% in the premarket on Thursday after the company said its oral GLP-1 receptor agonist ...

So far this year, Pfizer shares have dropped 17.4%, while Novo Nordisk's stock has tumbled 24% and Lilly shares have slipped 3.2%. The SPDR S&P Pharmaceuticals ETF XPH has shed 12.1% year to date and ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

FacebookTweetPin The stock market is climbing today, with companies gaining across the board as President Donald Trump has ...

The market turbulence unleashed by President Donald Trump’s tariff policies will likely evaporate the trickle of biotech IPOs ...

Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Metsera, Inc. (MTSR – Research Report) today and set a price target ...

Despite several big deals that buoyed the numbers, North America early- and seed-stage investment declined to multiquarter lows in Q1, and reported round counts fell across stages.